Cara Therapeutics Stock News

Shares of Cara Therapeutics Inc (NASDAQ:CARA) have been assigned a consensus recommendation of “Buy” from the eight brokerages that are currently covering the stock, Marketbeat.com reports. One re

Zacks Investment Research downgraded shares of Cara Therapeutics (NASDAQ:CARA) from a buy rating to a hold rating in a report issued on Wednesday, Zacks.com reports. According to Zacks, “Cara Therap

It is not uncommon to see companies perform well in the years after insiders buy shares. The flip side of that is that...

Goldman Sachs Group Inc. decreased its position in Cara Therapeutics Inc (NASDAQ:CARA) by 16.0% during the 4th quarter, according to its most recent filing with the SEC. The institutional investor own

Bank of America Corp DE lifted its holdings in shares of Cara Therapeutics Inc (NASDAQ:CARA) by 133.8% during the 4th quarter, Holdings Channel.com reports. The firm owned 421,581 shares of the biopha

Franklin Resources Inc. decreased its holdings in Cara Therapeutics Inc (NASDAQ:CARA) by 2.1% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission

STAMFORD, Conn., April 08, 2020 -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed.

STAMFORD, Conn., April 08, 2020 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and...

Brokerages expect Cara Therapeutics Inc (NASDAQ:CARA) to post ($0.64) earnings per share (EPS) for the current quarter, according to Zacks Investment Research. Five analysts have provided estimates fo

Cubist Systematic Strategies LLC increased its holdings in Cara Therapeutics Inc (NASDAQ:CARA) by 358.5% during the fourth quarter, according to its most recent 13F filing with the Securities and Exch

Advisor Group Inc. reduced its position in Cara Therapeutics Inc (NASDAQ:CARA) by 41.2% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Comm

Equities research analysts predict that Cara Therapeutics Inc (NASDAQ:CARA) will announce $4.83 million in sales for the current quarter, Zacks Investment Research reports. Five analysts have issued e

Cara Therapeutics Inc (NASDAQ:CARA) shot up 5.2% during trading on Monday . The stock traded as high as $13.38 and last traded at $13.26, 370,140 shares traded hands during mid-day trading. A decline

Corporate Highlights

Gainers VIVO Cannabis (OTC: VVCIF) stocks closed up 23.57% at $0.18 Meridian Bioscience (NASDAQ:) stocks closed up 13.37% at $7.97 The Flowr (OTC: FLWPF) stocks...